Gene therapy formulation

Optimize quality & potency across AAV serotypes & scales

Formulation screening

- High-throughput screening
- Forced degradation studies
- Long-term stability studies

Supportive studies

- Filter & mixing studies
- Manufacturing compatibility
- Hold-time studies

In-use studies

- Device compatibility
- Dosing procedure suitability

Gene therapy formulation that is closely linked to downstream & analytical processes

- Buffer & excepient selection
- Stability testing
- Confirmation of device compatibility & dosing procedure
- Low-volume high-throughput for better results from less material
- Rapid rebuffering & analytical testing
- Shorter development cycles & reduced barriers to final formulation
- Collaborative regulatory data documentation & submission

Proven Formulation Expertise



Before vs. after optimization of PS80 levels in an AAV formulation

Advanced Analytics & Developability

Formulation development is tightly intertwined with the analytical and downstream departments to tailor processes and streamline tech transfer.

Gyros ELISA



NanoDSF

DLS

Stunner

BMI

UNAGI Automated Rebuffering

ascend

ascend-adv.com business@ascend-adv.com

Aim higher

ADVANCED THERAPY MANUFACTURING SPECIALISTS